IMPORTANCE It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS).
L ipoprotein(a) [Lp(a)], a particle containing apolipoprotein B100 and apolipoprotein (a), may promote atherosclerosis, thrombosis, and consequent cardiovascular events. 1 Epidemiological and genetic data suggest that a high level of Lp(a) is an independent risk factor for incident cardiovascular disease. 2, 3 For patients with established stable coronary heart disease, an association of Lp(a) with cardiovascular risk has been inconsistent, and it has been suggested that such an association may depend on a concurrent high concentration of low-density lipoprotein cholesterol (LDL-C). 4, 5 Patients with acute coronary syndrome (ACS) are at high risk for recurrent ischemic cardiovascular events, despite highintensity statin treatment and other secondary prevention strategies. It is uncertain whether Lp(a) is an independent risk factor for further cardiovascular events after ACS, particularly when LDL-C is controlled. In addition, Lp(a) is a positive acute-phase reactant with increased concentration for several weeks following ACS. 6, 7 Therefore, the predictive value of Lp(a) after ACS may be more reliably determined after a period of clinical stabilization.
If residual cardiovascular risk after ACS were associated with levels of Lp(a), the findings might suggest Lp(a) as an additional target of therapy. This possibility assumes additional relevance in light of new treatments that reduce levels of Lp(a) substantially, including PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies 8 and antisense oligonucleotide to apolipoprotein (a). 9 This nested case-cohort analysis used data from the dal-Outcomes randomized clinical trial to determine whether Lp(a) concentration is associated with the risk of major adverse cardiovascular events following ACS.
Methods

Study Population
This study was an ad hoc analysis of the dal-Outcomes trial, a randomized, double-blind comparison of dalcetrapib, a cholesteryl ester transfer protein inhibitor, to placebo in 15 871 patients with recent ACS. Trial design and principal results have been described previously. 10, 11 The trial was performed between April 2008 and September 2012 at 935 sites in 27 countries. The institutional review board of each site approved the trial, and all participants provided informed consent. Data analysis for the present study was conducted from June 8, 2016, to April 21, 2017. Qualifying patients were randomly assigned to receive dalcetrapib, 600 mg daily, or matching placebo, beginning 4 to 12 weeks after an index ACS event, when they were clinically stable and had completed all planned coronary revascularization procedures. Exclusion criteria included New York Heart Association class III or IV symptoms of heart failure or class II symptoms if the left ventricular ejection fraction was found to be 40% or less, uncontrolled hypertension, a serum creatinine level higher than 2.2 mg/dL (to convert to micromoles per liter, multiply by 88.4), or a triglyceride level higher than 400 mg/dL (to convert to millimoles per liter, multiply by 0.0113). Evidence-based treatments, including statins, were encouraged for all patients.
Measurement of Lp(a)
The level of Lp(a) was measured in serum samples at baseline (randomization visit) and at 3 months of assigned treatment by immunoturbidimetric assay (Cobas; Roche Diagnostics) with an operating range of 3 to 100 mg/dL (to convert to micromoles per liter, multiply by 0.0357), an intra-assay coefficient of variation of 0.5% to 1.3%, and an interassay coefficient of variation of 1.2% to 1.7%.
Nested Case-Cohort Design
The dal-Outcomes trial included a nested case-cohort study to evaluate the association between baseline levels of circulating biomarkers and the risk of a subsequent primary endpoint event, defined as death due to coronary heart disease, a major nonfatal coronary event (myocardial infarction [MI], hospitalization for unstable angina, or resuscitated cardiac arrest), or a fatal or nonfatal ischemic stroke. These events were adjudicated by a blinded, independent event adjudication committee.
The analysis data set included 4139 individuals. Case patients (n = 969) were patients with a baseline measurement of Lp(a) who experienced a primary end-point event. Control patients (n = 3170) for each case patient were randomly selected from patients who were event free at the time of a case event and who had the same type of index ACS (unstable angina or MI) as that of the respective case patients.
Case-cohort regression was used to infer an association between Lp(a) levels and the hazard of an end-point event. The analysis included 1146 primary end-point events (969 among case patients and 177 among control patients). The 177 events among the control patients occurred after their matched case event time. Analyses used log 2 Lp(a) to remove the positive skew in the distribution of Lp(a) levels. Results are reported as the hazard ratio (HR) for a primary end-point event for each doubling of baseline Lp(a) level, with the corresponding 95% CI and 2-sided P value.
Adjusted analyses included as covariates 16 baseline demographic, medical history, laboratory, and treatment variables, as indicated in the Table. The cumulative distribution of Lp(a) was compared in case patients and control patients using the Wilcoxon rank sum test. Results are reported as 95%
Key Points
Question For patients with recent acute coronary syndrome, is the concentration of lipoprotein(a) associated with the subsequent risk of major ischemic cardiovascular events?
Findings This case-cohort analysis of 969 cases and 3170 controls participating in the dal-Outcomes randomized clinical trial found that the concentration of lipoprotein(a) measured 4 to 12 weeks after acute coronary syndrome had no association with the risk of death due to coronary heart disease, major nonfatal coronary events, or stroke.
Meaning This finding calls into question whether treatment to reduce lipoprotein(a) levels will thereby reduce the risk of ischemic cardiovascular events after acute coronary syndrome. ; P = .62). In addition, case patients were more likely to have a history of hypertension, diabetes, prior MI, coronary revascularization, or stroke; higher levels of LDL-C, triglycerides, and hemoglobin A 1c ; and a lower estimated glomerular filtration rate. Lipoprotein (a) concentration was positively associated with prior MI or coronary revascularization and the level of LDL-C. It was negatively associated with male sex, diabetes, and levels of triglycerides, and the estimated glomerular filtration rate. Approximately 50% of case patients and 50% of control patients were treated with dalcetrapib, a finding consistent with the neutral effect of dalcetrapib in the main analysis of the trial. 10 Median (IQR) concentration of Lp(a) was 12.9 (4.7-55) mg/dL in case patients and 12.1 (4.6-49) mg/dL in control patients. Figure 1 shows that the cumulative distribution of Lp(a) did not differ between case patients and control patients at P = .16. The HR (case to control) for a doubling of baseline Lp(a) level was 1.03 (95% CI, 0.98-1.08; P = .21) in unadjusted analysis and 1.01 (95% CI, 0.96-1.06; P = .66) in adjusted analysis. To determine if an association between Lp(a) and cardiovascular risk was evident at higher levels of Lp(a), we examined HRs by decile of baseline Lp(a) level (Figure 2) . Again, no significant association was evident, even in the highest deciles. Finally, Lp(a) was dichotomized at 50 mg/dL. The resulting HR (≥50/<50 mg/dL) of 1.16 (95% CI, 0.97-1.39; Because the operating range for the Lp(a) assay was 3 to 100 mg/dL (to convert to micromoles per liter, multiply by 0.0357), any concentration of 100 mg/dL or higher is indicated at 100 mg/dL. The cumulative distribution of Lp(a) did not differ between case patients and control patients at P = .16, as determined by the Wilcoxon rank sum test. Research Brief Report Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events P = .11) does not indicate a significant association of higher levels of Lp(a) with cardiovascular risk. At 3 months of assigned treatment, there were small decreases in the concentration of Lp(a) among patients treated with dalcetrapib (mean [SD] change from baseline, −1.7 [6.6] mg/dL [n = 1717]; P < .001) and among patients treated with placebo (−0.6 [6.2] mg/dL [n = 1760]; P < .001). The change from baseline was greater with dalcetrapib than with placebo (P < .001).
Discussion
Although Lp(a) levels appear to be associated with cardiovascular risk in initially healthy individuals, the present analysis indicates that there is no association between Lp(a) level and risk of ischemic cardiovascular events after ACS. Our neutral results are consistent with the findings from the Cholesterol and Recurrent Events (CARE) trial, the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial, the Ludwigshafen Risk and Cardiovascular Health (LURIC) observational study of patients with prior MI or stable coronary heart disease as well as the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial of patients with ACS. 4, 12 The results are also consistent with those of an analysis of the Effect of Rosuvastatin Versus Atorvastatin (SATURN) trial, in which Lp(a) level was not associated with progression or regression of coronary atheroma volume assessed by intravascular ultrasonography. 13 However, findings from the present analysis contrast with those from the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial of patients with established, chronic atherosclerotic cardiovascular disease, 14 as well as the Scandinavian Simvastatin Survival Study (4S) of patients with coronary heart disease and pronounced elevation of serum cholesterol levels. 15 In these studies, significant associations were found between Lp(a) level and major adverse cardiovascular events (AIM-HIGH trial) or between Lp(a) level and death (4S). The disparate findings among these studies are not readily reconciled and are unlikely to be explained by differences in baseline Lp(a) levels (median range, 5-17 mg/dL in the previous studies vs 13 mg/dL in the present analysis), baseline LDL-C levels (nearly identical in the AIM-HIGH trial and the present analysis, with a mean level of approximately 75 mg/dL), or duration of follow-up (2 to 10 years in the neutral analyses vs 3 to 5 years in the positive analyses).
In studies that specifically evaluated patients with ACS, the congruent neutral findings from the PROVE-IT 4 
Strengths and Limitations
The strengths of this analysis include a large number of cardiovascular end points, the broad use of contemporary secondary prevention therapies, and ascertainment of Lp(a) after any acutephase effects on its levels. Its limitations include the possibility that the analysis was underpowered to detect an association of Lp(a) level with cardiovascular outcomes restricted to the upper range of Lp(a) concentrations. Other limitations are those inherent to case-cohort studies, which are subject to confounding because only a subset of the entire trial cohort had biomarker measurements. Matching and covariate adjustments were used to account for the most likely confounders, but potential confounding by other unmeasured covariates cannot be excluded.
Conclusions
Although Lp(a) is believed to be an atherogenic lipoprotein, the present analysis indicates that Lp(a) concentration does not predict the risk of ischemic cardiovascular events following ACS among patients who receive current evidence-based therapies. Filled circles and vertical lines indicate the hazard ratio and 95% CI for deciles 2 to 10 of Lp(a), relative to decile 1 [Lp(a) <2.9 mg/dL]. The decile ranges for deciles 2 to 10 of Lp(a) are 2.9 to less than 3.6 mg/dL (decile 2), 3.6 to less than 5.7 mg/dL (decile 3), 5.7 to less than 8.3 mg/dL (decile 4), 8.3 to less than 12 mg/dL (decile 5), 12 to less than 20 mg/dL (decile 6), 20 to less than 37 mg/dL (decile 7), 37 to less than 62 mg/dL (decile 8), 62 to less than 91 mg/dL (decile 9), and 91 to greater than 100 mg/dL (decile 10). To convert to micromoles per liter, multiply by 0.0357.
